Abarelix
A medication used in the treatment of prostate cancer
| Abarelix | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Intramuscular injection |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 183552-38-7 |
| PubChem | 6918285 |
| DrugBank | DB00096 |
| ChemSpider | 5293517 |
| KEGG | D02906 |
Abarelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist) used in the treatment of prostate cancer. It is marketed under the trade name Plenaxis. Abarelix works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn reduces the production of testosterone by the testes.
Medical uses[edit | edit source]
Abarelix is primarily used in the treatment of advanced prostate cancer to reduce the levels of testosterone, which can stimulate the growth of cancer cells. It is administered via intramuscular injection.
Mechanism of action[edit | edit source]
Abarelix is a synthetic decapeptide that acts as a gonadotropin-releasing hormone antagonist. By binding to the GnRH receptors in the pituitary gland, it prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression leads to a decrease in testosterone production by the testes, which is beneficial in the treatment of hormone-sensitive prostate cancer.
Side effects[edit | edit source]
Common side effects of Abarelix include hot flashes, fatigue, and nausea. Serious side effects may include allergic reactions and cardiovascular events. Patients receiving Abarelix should be monitored for signs of hypersensitivity and other adverse reactions.
History[edit | edit source]
Abarelix was developed as an alternative to GnRH agonists, which initially stimulate the release of LH and FSH before suppressing them, potentially causing a temporary surge in testosterone levels. Abarelix was approved for medical use in the early 2000s.
See also[edit | edit source]
- Prostate cancer
- Gonadotropin-releasing hormone antagonist
- Luteinizing hormone
- Follicle-stimulating hormone
- Testosterone
References[edit | edit source]
External links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
